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Prevention of multidrug resistance (MDR) in
osteosarcoma by NSC23925
X Yang1,2, P Yang1, J Shen1, E Osaka1, E Choy1, G Cote1, D Harmon1, Z Zhang2, H Mankin1, F J Hornicek1
and Z Duan*,1
1Sarcoma Biology Laboratory, Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital and Harvard
Medical School, 100 Blossom Street, Jackson 1115, Boston, MA 02114, USA and 2Department of Gynaecology and Obstetrics, The
Third Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China
Background: The major limitation to the success of chemotherapy in osteosarcoma is the development of multidrug resistance
(MDR). Preventing the emergence of MDR during chemotherapy treatment has been a high priority of clinical and investigational
oncology, but it remains an elusive goal. The NSC23925 has recently been identified as a novel and potent MDR reversal agent.
However, whether NSC23925 can prevent the development of MDR in cancer is unknown. Therefore, this study aims to evaluate
the effects of NSC23925 on prevention of the development of MDR in osteosarcoma.
Methods: Human osteosarcoma cell lines U-2OS and Saos were exposed to increasing concentrations of paclitaxel alone or in
combination with NSC23925 for 6 months. Cell sublines selected at different time points were evaluated for their drug sensitivity,
drug transporter P-glycoprotein (Pgp) expression and activity.
Results: We observed that tumour cells selected with increasing concentrations of paclitaxel alone developed MDR with
resistance to paclitaxel and other Pgp substrates, whereas cells cultured with paclitaxel–NSC23925 did not develop MDR and cells
remained sensitive to chemotherapeutic agents. Paclitaxel-resistant cells showed high expression and activity of the Pgp, whereas
paclitaxel–NSC23925-treated cells did not express Pgp. No changes in IC50 and Pgp expression and activity were observed in cells
grown with the NSC23925 alone.
Conclusions:Our findings suggest that NSC23925 may prevent the development of MDR by specifically preventing the overexpression
of Pgp. Given the significant incidence of MDR in osteosarcoma and the lack of effective agents for prevention of MDR, NSC23925
and derivatives hold the potential to improve the outcome of cancer patients with poor prognosis due to drug resistance.
Osteosarcoma is one of the most common and aggressive primary
malignant bone tumours in childhood and adolescence. Current
standard treatment of osteosarcoma involves surgical resection and
combination chemotherapy (Marina et al, 2004; Chou et al,
2008). Although this therapy helps tumour cytoreduction and
remission rate, the long-term survival rate remains at B60–70%
(Marina et al, 2004; Sakamoto and Iwamoto, 2008). Osteosarcoma
is still characterised by frequent relapse and metastatic disease that
is associated with the development of multidrug resistance
(MDR) to chemotherapy in late stages (Chou and Gorlick, 2006;
Dieudonne et al, 2010). Tumour cells that are initially sensitive to
chemotherapeutic drugs often develop resistance to those drugs as
well as to other functionally and structurally unrelated anticancer
agents later, thus limiting the overall utility of chemotherapeutic
drugs (Agarwal and Kaye, 2003; Chou and Gorlick, 2006). The
development of MDR is a major obstacle to cancer chemotherapy
and is a significant challenge to successful cancer treatment (Gillet
and Gottesman, 2010). Several mechanisms have been shown to
potentiate osteosarcoma to become resistant to chemotherapeutic
agents (Chou and Gorlick, 2006). One of the best characterised
MDR mechanisms is overexpression of ATP-binding cassette
(ABC) drug transporters P-glycoprotein protein (Pgp) that causes
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decreased drug uptake and increased drug efflux in MDR cells
(Gottesman et al, 2002; Ozben, 2006; Higgins, 2007). P-glycoprotein
protein is the protein product of multidrug resistance gene 1
(MDR1), and acts as an energy-dependent drug efflux pump
requiring two ATPs as the energy source to pump out many
structurally unrelated chemotherapeutic drugs (Gottesman et al,
2002). Overexpression of Pgp has been found in multiple MDR
osteosarcoma cell lines and osteosarcoma drug resistance tissues
(Bodey et al, 1995; Suto et al, 1998; Chano et al, 2004; Okada et al,
2006; Susa et al, 2010). Strategies of reversing and preventing MDR
by targeting Pgp have been studied extensively in different MDR
model systems including osteosarcoma but with limited success
(Decaudin et al, 2002; Ryu et al, 2010; Kobayashi et al, 2012).
Most of the previous investigations have been focussed on the
reversal rather than prevention of Pgp-mediated MDR. Four
generations of Pgp inhibitors have been developed (Shukla et al,
2011), including verapamil, PSC833 (valspodar), VX-710 (birico-
dar), XR9576 (tariquidar), R101933 (laniquidar) and a natural
product, curcumin (Lin et al, 2007; Gupta et al, 2012). However,
preventing the development of MDR during the course of
chemotherapy and exploring the underlying molecular machinery
rather than reversing MDR once it has arisen may fundamentally
aid in the design of strategies for overcoming MDR in cancer. In
recent years, several studies have investigated the prevention of
initiation of MDR in cancer after chemotherapy drug treatment
(Batrakova et al, 2006; Tooker et al, 2007; Sharma et al, 2008).
A number of drugs, such as verapamil, cyclosporin A (CsA),
VX710, XR9576, P85 (Pluronic 85) and LGD1069 (bexarotene)
have been tested as the preventers that avert the development of
MDR (Cocker et al, 2001; Yen et al, 2004; Yen and Lamph, 2006).
Several clinical trials have been performed using these preventers
in different types of cancer patients (Baer et al, 2002; Minderman
et al, 2004; Kelly et al, 2011). However, significant effects on
prevention of MDR for most of these preventers have not been
established, and notable survival benefits have not been shown in
clinical trials (Gandhi et al, 2007; Lhomme et al, 2008; Kolitz et al,
2010; O’Brien et al, 2010). Therefore, development of more potent
and selective MDR preventers is needed.
The NSC23925 (2-(4-methoxyphenyl)-4-quinolinyl) (2-piper-
idinyl) methanol) is a small molecular compound that was
identified as an effective and selective inhibitor of Pgp in previous
studies. It was demonstrated that NSC23925 has the ability to
reverse Pgp-mediated MDR in ovarian cancer by stimulating Pgp
ATPase activity in vitro. The NSC23925 was 20-fold more potent
than verapamil and 50-fold more potent than CsA at the same
concentrations to reverse drug resistance (Duan et al, 2009a).
Importantly, the combination of paclitaxel and NSC23925
produced a significant inhibitory effect on the growth of
xenograft ovarian cancer MDR tumour models as compared
with animals treated with paclitaxel alone (Duan et al, 2012).
However, whether NSC23925 is able to prevent the development
of MDR in cancer is unknown. Therefore, in this study,
we evaluated the effects of NSC23925 on the prevention of
the development of MDR in the osteosarcoma cell lines U-2OS
and Saos.
MATERIALS AND METHODS
Cell lines, drugs and antibodies. Human osteosarcoma cell lines
U-2OS and Saos were purchased from American Type Culture
Collection (ATCC, Manassas, VA, USA). Both of the cell lines were
routinely cultured in RPMI-1640 (Life Technologies, Grand Island,
NY, USA) supplemented with 10% fetal bovine serum (FBS) and
1% penicillin/streptomycin (Life Technologies) in 5% CO2–95% air
atmosphere at 37 1C.
Prior analyses have demonstrated that there are two chiral
centres in the structure of NSC23925 that lead to four different
isomers. Isomer 11 of NSC23925 is the most potent one for the
reversal of MDR (Duan et al, 2012). Therefore, isomer 11 was used
in this study. Isomer 11 of NSC23925 (abbreviated as NSC23925)
was synthesised by ChemPartner Co. (Chengdu, China) and has
been validated to reverse MDR (Duan et al, 2012). Paclitaxel,
docetaxel, doxorubicin, vincristine, gemcitabine, cisplatin and
methotrexate were obtained from the pharmacy at the Massachusetts
General Hospital. PM-00104 was supplied by PharmaMar
(Madrid, Spain). The mouse monoclonal antibodies to human
Pgp and MRP1 were purchased from Sigma-Aldrich (St Louis,
MO, USA). The mouse monoclonal antibody to human BCRP was
acquired from EMD Millipore (Bedford, MA, USA).
Development of resistant osteosarcoma cell lines. To evaluate
the effect of NSC23925 on preventing the development of
paclitaxel resistance, 1 105 U-2OS and Saos cells were seeded
in 75 cm2 tissue culture flasks containing RPMI-1640 with 10%
FBS and 1% penicillin/streptomycin. Establishment of the resistant
osteosarcoma cells lines followed similar previously described
protocols (Cocker et al, 2001; Sharma et al, 2008). The culture
medium was supplemented with either 0.0001mM paclitaxel alone,
the combination of 0.0001mM paclitaxel and 1 mM NSC23925 or
1 mM NSC23925 alone. When growth of the cells reached 90%
confluence, the cells were harvested and reseeded at the density of
1 105 cells/flask, and the concentration of paclitaxel was
increased. At different selection points, cell sublines were stored
in liquid nitrogen for further studies. The MDR cell line U-2OSR2,
which was previously established from U-2OS, was used as a
control (Duan et al, 2009b).
Cytotoxicity assay. Cytotoxicity of anticancer drugs in selected
cell sublines was assessed by MTT assay as previously described
(Duan et al, 2012). Briefly, cytotoxicity of anticancer drugs in
selected cell sublines was assessed by MTT assay. Cells were seeded
in 96-well plates at the density of 3.5 103 cells per well and
exposed to different concentrations of anticancer drugs for 5 days.
Subsequently, 20 ml MTT (Sigma-Aldrich) was added to each well.
After incubation for 4 h, the resulting formazan products were
dissolved with acid-isopropanol. The absorbance at a wavelength of
490 nm was measured on a SpectraMax Microplate Spectro-
photometer (Molecular Devices LLC, Sunnyvale, CA, USA).
Experiments were performed in triplicate. Absorbance values were
normalised assigning the value of the cells in medium without drug
to 1.0 and the value of the no-cell control to 0.
Western blot assay. To evaluate the protein expression of Pgp and
other ABC transporters including MRP1 and BCRP in different
selected cell sublines, total proteins were extracted with 1 RIPA
lysis buffer (Upstate Biotechnology, Charlottesville, VA, USA).
Protein concentrations were evaluated by the DC Protein Assay
(Bio-Rad, Hercules, CA, USA), and western blot analysis was then
performed as previously described (Duan et al, 2009b). Briefly,
20 mg of total protein was resolved on NuPAGE 4–12% Bis-Tris
Gel (Life Technologies) and transferred onto nitrocellulose
membrane (Bio-Rad). The membrane was then blocked in
Tris-buffered saline with 0.1% Tween-20 (TBST) containing 5%
nonfat milk for 2 h and subsequently probed with primary
antibodies (dilution: 1 : 1000) at 4 1C overnight. After washing
three times with TBST, they were further incubated with respective
secondary antibodies (LI-COR Biosciences, Lincoln, NE, USA) in a
dilution of 1 : 20 000 for 1 h at room temperature. The membranes
were washed again with TBST and rinsed with PBS. Finally,
membranes were scanned using Odyssey CLx equipment (LI-COR
Biosciences).
Immunofluorescence assay. Different U-2OS cell sublines were
grown in 24-well plate for 48 h and fixed in 3.7% buffered
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paraformaldehyde. After permeating with methanol for 20min, the
cells were blocked with 1% BSA in PBS for 1 h. Subsequently, the
cells were incubated with Pgp antibody (dilution: 1 : 50) at 4 1C
overnight. After washing three times with PBS, the cells were then
incubated with Alexa Fluor 594 (Red)-conjugated goat anti-mouse
antibody (Invitrogen, Carlsbad, CA, USA) in a dilution of 1 : 1000
for half an hour. The nuclei were stained with 1mgml 1 Hoechst
33342 (Life Technologies). Images were obtained by Nikon Eclipse
Ti-U fluorescence microscope (Nikon Instruments, Inc., Melville,
NY, USA) equipped with a SPOT RT digital camera (Diagnostic
Instruments, Inc., Sterling Heights, MI, USA).
Drug uptake assay determined by fluorescence microscopy. For
visualisation of the intracellular accumulation level of Pgp
substrate Calcein AM and Rhodamine 123 (R123) in different
U-2OS cell sublines, 2 104 cells were seeded in 12-well plate in
duplicate the day before the assay. Cells were then incubated with
either 0.25 mM Calcein AM or 1mM R123 in RPMI-1640 medium
for 2 h at 37 1C. After washing the cells with PBS, 1mgml 1
Hoechst 33342 was used to stain nuclei. Images were acquired by
Nikon Eclipse Ti-U fluorescence microscope equipped with a
SPOT RT digital camera.
Calcein AM retention assay. At 1 day before the assay, 2 104
cells of different U-2OS cell sublines were cultured in a 96-well
plate in triplicate. Cells were then incubated with 0.25 mM calcein
AM for 15min. After rinsing with cold culture medium, the cell
fluorescence was measured at absorption wavelength 494 nm and
emission wavelength 517 nm on a SPECTRAmax GeminXS
fluorescent spectrophotometer (Molecular Devices), and normal-
ised for cellular protein levels as determined by DC Protein Assay.
The absorbance values were normalised against the value of the
parental U-2OS and Saos cells.
R123 accumulation and efflux assay. Different U-2OS cell
sublines were seeded at 4 104/well in two separate 96-well plates
in triplicate 1 day before the assay. Both plates were washed three
times with serum-free RPMI-1640 on day 2, and the cells were then
incubated with 3.2 mM R123 in serum-free RPMI-1640 culture
medium for 1 h at 37 1C. One plate was gently washed three times
with ice-cold PBS to remove extracellular R123 and lysed in
Triton X-100 (1.0%). Intracellular R123 content was determined
using a SPECTRAmax GeminXS fluorescent spectrophotometer
(lex¼ 492 nm, lem¼ 535 nm) and normalised for cellular protein
levels as determined by DC Protein Assay. This value was labeled
as Ra. The second plate was washed three times with ice-cold
serum-free RPMI-1640 culture medium, and incubated with
serum-free RPMI 1640 for another 1 h. Subsequently, cells were
washed three times with ice-cold PBS and lysed in Triton X-100
(1.0%). R123 content was determined as described above and the
values were labeled as Re. The relative R123 cellular efflux level was
calculated by (RaRe)/Ra. The absorbance values were normalised
against the value of the parental U-2OS cells.
Statistical analysis. Statistical analysis was done using GraphPad
Prism 5 software (GraphPad Software, Inc., La Jolla, CA, USA).
Data were presented as the mean±s.d. For comparison between
two groups, a two-sided Student’s t-test was used. Po0.05 value
was considered as statistically significant.
RESULTS
NSC23925 prevents the emergence of MDR during paclitaxel
treatment. To establish MDR cell sublines, osteosarcoma cell lines
U-2OS and Saos were cultured either with increasing concentra-
tions of paclitaxel alone or in combination with 1mM NSC23925
(paclitaxel–NSC23925). U-2OS cells selected with paclitaxel alone
(U-2OS/paclitaxel) grew steadily in the presence of 0.2mM
paclitaxel in culture medium after 6 months of drug exposure.
In contrast, cells cultured with paclitaxel–NSC23925 combination
(U-2OS/paclitaxel–NSC23925) were unable to grow in the medium
with more than 0.006 mM paclitaxel (Figure 1A). Similar to U-2OS,
Saos cells selected with paclitaxel alone (Saos/paclitaxel) showed
stable growth in the presence of 0.06 mM paclitaxel after half-year,
whereas cells cultured with paclitaxel–NSC23925 combination
(Saos/paclitaxel–NSC23925) could not tolerate more than 0.001 mM
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Figure 1. Development of drug resistance in U-2OS and Saos cell lines during paclitaxel treatment. (A) The time course of development of
paclitaxel resistance in U-2OS cell line in the absence or in the presence of 1 mM NSC23925. (B) The time course of development of paclitaxel
resistance in Saos cell line. Two independent experiments were established simultaneously in cells selected with paclitaxel alone, and resistance
U-2OS and Saos cell lines developed on both occasions (paclitaxel-1 and paclitaxel-2). The experiments of cells cultured with the paclitaxel–
NSC23925 combination were also repeated independently two times, in which the use of NSC23925 prevented the development of resistance to
paclitaxel on both occasions (paclitaxel–NSC23925-1 and paclitaxel–NSC23925-2). Different selection points for cell sublines indicated by arrows
in the time course of paclitaxel-1 and paclitaxel–NSC23925-1 were used in the further experiments.
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paclitaxel in culture medium (Figure 1B). Two independent
experiments were established simultaneously in osteosarcoma cells
selected with paclitaxel alone, and resistant U-2OS and Saos cell
lines were developed in all of these experiments. The experiments of
cells cultured with paclitaxel–NSC23925 combination were also
repeated independently two times, and NSC23925 was shown to
prevent the introduction and development of resistance to paclitaxel
in both of these events. Cell sublines used for further experiments
were harvested and frozen at different selection points, as shown by
arrows in Figure 1A and B. In addition, U-2OS and Saos cells
cultured with 1mM NSC23925 (U-2OS/NSC23925, Saos/NSC23925)
alone were grown stably for 2 months (data were not shown).
The IC50 of paclitaxel was then evaluated to further determine
paclitaxel resistance. As expected, the IC50 of paclitaxel in cell
sublines revealed the same trend as their tolerance to paclitaxel
during selection (Figure 2A and B). The IC50 of paclitaxel in cells
selected with paclitaxel alone increased as the time and
concentration of drug exposure increased. U-2OS cells selected
withX0.06 mM of paclitaxel alone showed significantly higher IC50
of paclitaxel as compared with the parental cells. An increase of
72.1-fold in IC50 of paclitaxel was observed in U-2OS cells selected
with 0.2mM paclitaxel alone (U-2OS/paclitaxel0.2) as compared
with parental cells. However, the IC50 of paclitaxel in cells cultured
with 0.006 mM paclitaxel–NSC23925 combination (U-2OS/pacli-
taxel0.006–NSC23925) increased by 0.8-fold only, further suggesting
that paclitaxel–NSC23925 combination prevented the development of
paclitaxel resistance. Specifically, the IC50 of paclitaxel in U-2OS/
paclitaxel0.2 cells was 40.1-fold as high as that of U-2OS/
paclitaxel0.006–NSC23925 cells (Figure 2A and Supplementary
Table 1). Similar results were shown in Saos cell sublines (Figure 2B
and Supplementary Table 2). There was no change in IC50 of
paclitaxel in cells cultured with 1mM NSC23925 alone (Figure 2).
Because paclitaxel–NSC23925 prevented the emergence
of paclitaxel resistance, we further examined whether this
combination could prevent acquired drug resistance to other
cytotoxic agents. The IC50 of docetaxel, doxorubicin, vincristine,
PM-00104, gemcitabine, cisplatin and methotrexate in U-2OS
cell sublines were used to examine the cross-resistance profiles.
U-2OS/paclitaxel0.2 cells revealed 28.9-fold increased cross-resistance
to doxorubicin, whereas U-2OS/paclitaxel0.006-NSC23925 cells
remained sensitive to doxorubicin. Sensitivity to other well-known
Pgp substrate drugs, such as docetaxel, vincristine and PM-00104,
was also notably reduced in U-2OS/paclitaxel0.2 cells. Nevertheless,
U-2OS/paclitaxel0.006–NSC23925 cells remained sensitive to doc-
etaxel, vincristine and PM-00104 (Figure 3 and Supplementary
Table 3). Therefore, cells selected with paclitaxel alone naturally
acquired MDR, whereas MDR did not develop in cells cultured
with paclitaxel–NSC23925 combination. These results, taken
together, indicated that NSC23925 has the ability to prevent the
emergence of MDR in cancer cells treated with paclitaxel. In
addition, the cytotoxicity of cisplatin and methotrexate that are
known to be unaffected by Pgp mechanisms were not altered in
U-2OS/paclitaxel0.006–NSC23925 and U-2OS/paclitaxel0.2 cells
(Figure 3 and Supplementary Table 3).
NSC23925 specifically prevents Pgp overexpression during
chemotherapeutic drug treatment. The expression levels of Pgp
in different cell sublines were evaluated to further identify the
underlying mechanisms of preventing MDR development by
NSC23925. Western blot analysis demonstrated that U-2OS/
paclitaxel and Saos/paclitaxel cells selected with X0.06 mM
paclitaxel alone expressed significantly higher levels of Pgp;
however, no significant induction of Pgp expression was observed
in U-2OS/paclitaxel–NSC23925 and Saos/paclitaxel–NSC23925
cells as compared with parental cells (Figure 4A and B). The
relative Pgp expression level was analysed by densitometry and the
results are presented in Figure 4C. The increase in Pgp level
detected in the different cell sublines showed a strong association
with the increase in the concentration of paclitaxel tolerated by
cells. These results suggested that exposure of cells to paclitaxel led
to overexpression of Pgp, and that increased Pgp expression level
was responsible for the emergence of MDR. NSC23925 can prevent
the development of MDR in cancer cells through the inhibition of
Pgp expression. These findings were further confirmed by
immunofluorescence. The U-2OS/paclitaxel0.2 cells displayed
significantly higher Pgp staining than U-2OS/paclitaxel0.006–
NSC23925 cells (Figure 4D). Cells selected with 1mM NSC23925
alone did not affect Pgp expression.
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Figure 2. The NSC23925 prevented the emergence of paclitaxel resistance during chemotherapeutic agents. (A) The IC50 of paclitaxel in U-2OS
parental cell and selected cell sublines. The labels correspond to U-2OS parental cells (U-2OS parental); cells cultured with 1 mM NSC23925 alone
(NSC23925 alone); cells cultured with 0.003mM paclitaxel in the presence of 1mM NSC23925 (0.003mM paclitaxel–NSC23925); cells selected with
0.006mM paclitaxel in the presence of 1mM NSC23925 (0.006mM paclitaxel–NSC23925); and cells selected with paclitaxel alone at different
concentrations: 0.003mM (0.003mM paclitaxel), 0.006mM (0.006mM paclitaxel), 0.01mM (0.01mM paclitaxel), 0.03mM (0.03mM paclitaxel), 0.06mM
(0.06mM paclitaxel), 0.1mM (0.1mM paclitaxel) and 0.2mM paclitaxel (0.2mM paclitaxel); U-2OSR2. (B) The IC50 of paclitaxel in Saos parental cell and
selected cell sublines. Data are presented as mean±s.d.
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It is well known that Pgp is not the sole mechanism of MDR.
Therefore, the expression level of other important drug transporter
proteins including BCRP and MRP1 was also assessed in different
cell sublines. All of the U-2OS and Saos cell sublines exhibited low
expression of BCRP, and protein expression of MRP1 was
undetectable (Figure 4A and B). No difference of MRP1 and
BCRP levels among the cell sublines revealed that MRP1 and
BCRP were not associated with the introduction of drug resistance
selected by paclitaxel treatment. Thus, these observations suggested
that NSC23925 specifically suppressed the expression of Pgp to
prevent the emergence of MDR during chemotherapeutic drug
treatment.
NSC23925 prevents decreased drug intracellular accumulation
by preventing the overexpression of Pgp during paclitaxel
treatment. The intracellular accumulation and efflux levels
of Pgp substrates were examined to confirm the functional
activity of the Pgp in different U-2OS cell sublines. U-2OS/
paclitaxel0.006–NSC23925 cells showed a considerable higher
intracellular accumulation of Calcein AM and R123 as
compared with U-2OS/paclitaxel0.2 cells. Notably, U-2OS/
paclitaxel0.006–NSC23925 cells showed similar Pgp substrate
intracellular accumulation levels when compared with parental
cells (Figure 5A and B). Furthermore, a statistical lower relative
efflux level of R123 was detected in U-2OS/paclitaxel0.006–
NSC23925 cells than in U-2OS/paclitaxel0.2 cells (Figure 5B). The
accumulation and efflux activity of Pgp substrates were consistent
with the degree of Pgp expression. In addition, cells with longer
exposure to NSC23925 alone had no obvious effect on Pgp activity.
These results strongly indicated that the increased expression of
Pgp resulted in the decreased intracellular accumulation and
increased efflux of Pgp substrates.
DISCUSSION
NSC23925 is a novel methoxyphenyl piperidinyl compound
(http://pubchem.ncbi.nlm.nih.gov/) with a molecular weight of
348 gmol 1. The information about the pharmacological action of
NSC23925 is lacking. Reflective of our findings that NSC23925 can
reverse MDR by stimulating Pgp ATPase activity and inhibiting
the function of Pgp in a variety of MDR cancer cells (Duan et al,
2009a, 2012), the present study further demonstrated that
NSC23925 has the ability to prevent the development of MDR in
human osteosarcoma U-2OS and Saos cells. The U-2OS and Saos
cells selected with paclitaxel alone developed a MDR phenotype
with resistance to paclitaxel and cross-resistance to Pgp substrates
doxorubicin, docetaxel, vincristine and PM-00104. However, cells
selected with paclitaxel–NSC23925 simultaneously remained
sensitive to chemotherapeutic agents. Interestingly, cells selected
with paclitaxel alone showed significant higher Pgp expression
than cells selected with paclitaxel–NSC23925 combination and
parental cells. Specifically, cells selected with paclitaxel–NSC23925
combination displayed similar Pgp expression level to their
parental cells. The extent of MDR in selected cells correlated with
the Pgp expression level. Furthermore, cells selected with paclitaxel
or paclitaxel–NSC23925 combination remained sensitive to non-
Pgp substrates cisplatin and methotrexate, and no changes in
BCRP and MRP1 expression were seen in different cell sublines.
Our findings indicate that NSC23925 can prevent the emergence of
MDR in osteosarcoma by specifically preventing the expression of
Pgp during chemotherapeutic drug treatment.
We observed that exposure of cells to paclitaxel led to
overexpression of Pgp, and increased Pgp expression level was
responsible for the emergence of MDR, consistent with previous
research results suggesting that overexpression of Pgp plays a
major role in the molecular mechanisms of MDR (Suto et al, 1998;
Gottesman et al, 2002; Ozben, 2006; Sharma et al, 2008). The Pgp
rapidly pumps out functionally and structurally distinct che-
motherapeutic drugs from cells, acting as an energy-dependent
membrane transporter. Therefore, overexpression of Pgp results in
reduced intracellular accumulation of drugs and prevents the drugs
from exerting their cytotoxic effects (Szakacs et al, 2006). Our data
showed that paclitaxel-selected drug-resistant cells displayed
decreased drug intracellular accumulation and enhanced drug
efflux. In comparison, cancer cells selected with paclitaxel–
NSC23925 combination showed similar drug uptake/efflux level
as parental sensitive cells. NSC23925 prevents the increased
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Figure 3. The NSC23925 inhibited the introduction of cross-resistance to chemotherapeutic agents. The U-2OS/paclitaxel0.006–NSC23925
cells showed sensitivity to paclitaxel (A), docetaxel (B), doxorubicin (C), vincrisine (D), PM-00104 (E) and gemcitabine (F), whereas
U-2OS/paclitaxel0.2 cells displayed resistance to these drugs. The cytotoxicity of cisplatin (G) and methotrexate (H) did not change in both
U-2OS/paclitaxel0.006–NSC23925 and U-2OS/paclitaxel0.2 cells. No changes in cytotoxicity of chemotherapeutic agents were seen in U-2OS/
NSC23925 cells. Data are presented as mean±s.d.
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expression of Pgp and therefore prevents increased efflux and/or
decreased influx of drugs during chemotherapy treatment. These
findings provide an indication of the mechanism by which
NSC23925 prevents the emergence of MDR in osteosarcoma
(Figure 6). NSC23925 specifically prevented the overexpression of
Pgp during the chemotherapeutic drug treatment that subsequently
allowed for the retention of intercellular drug accumulation and
decreased drug efflux. Consequently, NSC23925 enabled tumour
cells to remain sensitive to chemotherapeutic drug and prevented
the emergence of MDR during chemotherapy treatment.
The inclusion of drugs or agents that can prevent the
development of MDR may enable patients who initially responded
to therapy to continue responding without the development of
MDR, and therefore provide significant clinical benefits. Prevent-
ing the overexpression of Pgp has been identified as an efficient
approach to inhibit the development of MDR during chemother-
apeutic drug treatment (Cocker et al, 2001; Yen and Lamph, 2006;
Zatelli et al, 2007). There are several drugs that act on the same
mechanism of preventing the development of MDR with
NSC23925 by suppressing the overexpression of Pgp, such as
PSC833, VX710 and P85 (Cocker et al, 2001; Batrakova et al, 2006;
Batrakova and Kabanov, 2008; Sharma et al, 2008). Unfortunately,
PSC833, a nonimmunosuppressive cyclosporin D derivative, was
shown to have pharmacokinetic interactions with paclitaxel and
inhibited non-MDR-related transporters (Kang et al, 2001; Bates
et al, 2004). Although VX-710 has no pharmacokinetic interactions
with paclitaxel and doxorubicin, myelosuppression and nonhae-
matologic toxicity have restricted this clinical application (Seiden
et al, 2002). The addition of VX-710 to vincristine and doxorubicin
therapy did not statistically enhance antitumour activity or survival
in recurrent small cell lung cancer (Gandhi et al, 2007). In the
present study, no significant changes on cell chemosensitivity, Pgp
expression or Pgp activity were observed in osteosarcoma cells with
longer exposure to NSC23925 alone in vitro. Moreover, both
NSC23925 alone and paclitaxel–NSC23925 combination do not
alter Pgp expression levels and activity in osteosarcoma cells. On
the basis of animal weight and mortality, no significant toxicity was
observed and the mice appeared to have tolerated it well when
NSC23925 was administered alone in our previous study (Duan
et al, 2012). Taken together, these observations may suggest that
NSC23925 has no pharmacokinetic interactions with paclitaxel,
and cannot increase drug toxicity in vitro. However, whether
NSC23925 has pharmacokinetic interactions with anticancer drugs
and other side effects in vivo deserves further investigation. P85 has
also been demonstrated to prevent the introduction of MDR1
phenotype by preventing the overexpression of Pgp in leukemia
cell line P388 as well as human breast carcinoma cell line MCF7
(Batrakova et al, 2006; Sharma et al, 2008). The IC50 of cells
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Figure 4. The NSC23925 specifically prevented Pgp overexpression during paclitaxel treatment. (A and B) Expression level of Pgp, BCRP and
MRP1 in different U-2OS and Saos cell sublines detected by western blot, respectively. Western blot analysis demonstrated that U-2OS/paclitaxel
and Saos/paclitaxel cells eventually expressed significantly higher Pgp. However, no significant change in Pgp expression level was observed in
U-2OS/paclitaxel–NSC23925 and Saos/paclitaxel–NSC23925 cells compared with parental cells. Increases in the Pgp level detected in the
different cell sublines showed a strong association with the increase in the concentration of paclitaxel tolerated by cells. No significant difference
of MRP1 and BCRP levels were observed among the different cell sublines. (C) Relative Pgp expression of western blot from (A and B) were
analysed by densitometry. The labels correspond to those given in (A and B). Data are presented as means±s.d. and analysed using Student’s
t-test (two tailed, unequal variance). Statistical comparisons between selected and parental cells are presented: *Po0.05, **Po0.005, ***Po0.001.
(D) Expression level of Pgp in U-2OS cell sublines analysed by immunofluorescence. The U-2OS/paclitaxel0.2 cells displayed significantly higher
Pgp staining than U-2OS/paclitaxel0.006–NSC23925 cells.
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selected with doxorubicin in the presence of P85 increased
6.13-fold in vitro and 5.58-fold in vivo as compared with parental
P388 cells. In contrast, IC50 of cells selected with paclitaxel in the
presence of NSC23925 increased by 0.8- or 0.6-fold compared with
IC50 of parental cells. Hence, NSC23925 may have a greater effect
on preventing the development of MDR than P85.
In summary, our findings indicate that NSC23925 can prevent
the development of MDR in osteosarcoma by specifically
preventing the overexpression of Pgp during chemotherapeutic
drug treatment. These results suggest that NSC23925 will be useful
in extending the long-term efficacy of chemotherapy by preventing
the development of Pgp-mediated MDR in the clinical setting.
U-2OS/NSC23925
U-2OS/paclitaxel0.006-
NSC23925
U-2OS/
paclitaxel0.006-NSC23925
U-2OS/paclitaxel0.2
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R123
Calcein AM accumulation
2.0
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*** ***
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R123 accumulation
Relative R123 efflux
Figure 5. Pgp activity in different cell sublines. (A) Drug intracellular accumulation images of U-2OS cell sublines incubated with Calcein AM and
R123. The U-2OS/paclitaxel0.006–NSC23925 cells demonstrated a significantly higher accumulation of Calcein AM and R123 as compared with
U-2OS/paclitaxel0.2 cells. (B) Calcein AM accumulation and R123 accumulation and efflux level in U-2OS cell sublines analysed by Microplate
Spectrofluorometer. The U-2OS/paclitaxel0.006–NSC23925 cells showed a statistically higher accumulation of Calcein AM, R123 and lower relative
efflux level of R123 than U-2OS/paclitaxel0.2 cells. Cells cultured with NSC23925 alone had no obvious effect on Pgp activity. Data are presented
as mean±s.d. and analysed using Student’s t-test (two tailed, unequal variance). Statistical comparisons between selected and parental cells are
presented: *Po0.05, **Po0.005, ***Po0.001.
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Figure 6. The mechanism by which NSC23925 acts to prevent the emergence of MDR in osteosarcoma. The U-2OS cells selected with paclitaxel
alone developed a MDR phenotype with resistance to Pgp substrates, as well as decreased drug intracellular accumulation and enhanced drug
efflux. However, NSC23925 specifically prevented overexpression of Pgp during chemotherapeutic drug treatment that subsequently allowed for
the retention of intercellular drug accumulation and decreased drug efflux. Consequently, NSC23925 enabled tumour cells to remain sensitive to
chemotherapeutic drugs and prevented the emergence of MDR during chemotherapy treatment.
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